Trial Profile
A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2016
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Carfilzomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PANORAMA-5
- Sponsors Novartis Pharmaceuticals
- 03 Oct 2016 Planned End Date changed from 1 Nov 2020 to 1 Feb 2021.
- 03 Oct 2016 Planned primary completion date changed from 1 Nov 2020 to 1 Feb 2021.
- 03 Oct 2016 Planned initiation date changed from 1 Jun 2016 to 1 Dec 2016.